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Commercial heparin has long been known to possess  anti-complementary as 
well as anti-coagulant  activity.  Early studies  identified  several  possible  sites  of 
inhibition by heparin ranging  from classical early (1) to late component 
functions (2, 3), and recent  studies  continue to reveal more than one possible 
site of inhibitory action. Heparin directly  inhibits  Clq binding to immune 
complexes (4),  interaction  of  Cis with C4 and C2 (5),  and binding of  C2 to C4b 
(6). Based on the demonstration of the anti-thrombin HI cofactor  activity  of 
heparin (7),  the potentiation  by heparin of  the effect  of  the C1 inhibitor  on Ci 
has been noted (8).  Heparin also  inhibits  formation or  binding of  the trimolecu- 
lar  complex, C5b67, as measured by the reactive  lysis  phenomenon (9).  Finally, 
heparin has been shown to inhibit  cobra venom factor  (CoVF)'-depondent C3 
inactivation  in  whole serum (10),  thereby indicating  an effect  on the generation 
or action  of  the C3 convertase formed from cobra venom factor,  B and I). 
Amplified C3 cleavage by the C3b-dependent C3 convertase (C3b,Bb) may. 
well determine whether the initial  activation  of  the complement sequence by 
the classical  or  by the alternative  pathway eventuates in effective  utilization  of 
the terminal components. The action  of  heparin was therefore  examined on the 
generation  and  natural  regulation of the amplification convertase. These 
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1Abbreviations  used  in  this  paper"  C3b,Bb,  C3b-dependent  C3  convertase;  C3bINA,  C3b 
inactivator; C3NeF, C3 nephritic factor; C-EDTA, rat serum diluted 1:20 in 0.04 M EDTA-GVB; 
CoVF,  Cobra  venom  factor;  CoVFBb,  CoVF-dependent  C3  convertase;  DGVB,  half-isotonic 
Veronal-buffered saline,  pH 7.5 contain~g 0.1% gelatin  and 2.5% dextrose;  DGVB ++, DGVB 
with 0.5 mM  magnesium and 0.15  mM  calcium;  EAC4b,3b, sheep erythrocyte  sensitized  with 
specific  antibody  and  bearing  the  major  cleavage  fragments of  C4  and  C3;  EDTA, ethylenodiamine 
tetraacetate;  EDTA-DGVB,  DGVB  containing 0.01 M  EDTA; EDTA-GVB,  isotonic  Veronal- 
buffered  saline  containing  0.1% gelatin  and 0.04  M  EDTA; P, properdin;  RPMC, rat peritoneal 
mast cell;  Z, average number of  hemolytic  sites/cell. 
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studies employed not only commercial  heparin,  a degraded  hog glycosamino- 
glycan mixture of average  12,000 mol wt, but also native rat peritoneal  mast 
cell  (RPMC)  heparin,  a  750,000  mol  wt  proteoglycan  (11).  Both  native  and 
commercial  heparin profoundly modulate  C3b-dependent amplification of the 
complement system by inhibition of C3b,Bb formation and prevention of BIll- 
mediated decay-dissociation of C3b,Bb. 
Materials and Methods 
Cobra  venom  (Reptile  Institute,  Inc.,  Silver  Spring,  Fla.),  Azure  A  (Fisher Scientific Co., 
Somerville, N. J.), Dowex l-C1 100-200 mesh (Bio-Rad Laboratories, Richmond, Calif.), Sepharose 
4B  (Pharmacia  Fine  Chemicals,  Piscataway,  N.  J.),  carboxymethyl  cellulose  (CM-52)  (Reeve 
Angel, Clifton, N.  J.),  Metrizamide  (Accurate Chemical &  Scientific Corp.,  Hicksville,  N.  Y.), 
and cetyltrimethyl ammonium bromide (Sigma Chemical Co., St.  Louis,  Mo.) were obtained as 
indicated. Aqueous preservative-free commercial sodium heparin, 1,000 U  (6.077 mg) per ml, was 
obtained  from  Fellows  Medical  Division,  Chromalloy  Pharmaceuticals,  Oak  Park,  Mich.  as 
manufactured by Elkins-Sinn, Inc., Cherry Hill, N. J. 
Native Heparin and Heparin Assays.  Commercial and RPMC  heparin were quantitated by 
metachromasia with Azure A  by a  modification (12)  of the method of Jaques et al.  (13) and by 
uronic  acid  content  using  the  carbazole  reaction  as  modified  by  Bitter  and  Muir  (14).  The 
commercial  and  RPMC  heparin  showed  similar dose  responses  and  were  quantitated  from  a 
reference curve linear between 10 and 100 pg/ml established with a  second commercial heparin 
preparation containing 130 U/mg (Schwarz/Mann Div.,  Becton, Dickinson &  Co.,  Orangeburg, 
N.  J.).  The anti-coagulant activities of commercial and RPMC  heparin were  determined in  a 
modified partial thromboplastin time assay (15) which gave a  linear dose response from 1 to 10 
~g with the second commercial heparin preparation used as the standard. 
Rat  mast  cells,  obtained  by  lavage  of 40-50  rat  peritoneal cavities,  were  pooled,  and  1-ml 
samples were each centrifuged through 22.5% metrizamide cushions of 2 ml (16), yielding 90-95% 
final purity. The mast cells were frozen and thawed six times and extracted with 1 M NaCl. The 
extract was applied to a  1  ×  20 cm column of Dowex 1 equilibrated in 1 M NaC1 and the column 
was eluted sequentially with 1, 3, and 4 M NaCl (11). The 3 M NaC1 eluate, which contained the 
RPMC  heparin  as  determined  by  metachromasia,  was  dialyzed  against  10  liters  of distilled 
water,  lyophilized,  redissolved in  2  M  NaCl and chromatographed on a  1  x  50 cm column of 
Sepharose 4B equilibrated in 2 M NaC1 (11). The RPMC heparin filtered with an average tool wt 
of approximately 750,000  and was pooled,  dialyzed,  lyophilized, and redissolved as required in 
0.15 M  NaCl for complement studies or further purification. Additional purification utilized a  1 
x  10 cm column containing CM-52 equilibrated in 1% cetyltrimethyl ammonium bromide. The 
heparin  precipitated  when  applied  to  the  column  (17)  and  was  eluted  at  2.4  M  NaCl  by 
application of a  concave logarithmic gradient from 0.15 to 5 M NaC1. The heparin was separated 
from the residual  cetyltrimethyl ammonium bromide by  the sequential addition of potassium 
iodide to  a  final molarity of 0.01  and an equal volume of chloroform  (17).  The heparin, which 
remained in the aqueous phase, was dialyzed against 10 liters of distilled water, lyophilized, and 
resuspended in 0.15  M  NaC1.  The RPMC  heparin anti-coagulant activity per microgram,  after 
the Sepharose 4B (11) or CM-52 step, was 15-18% of the activity of commercial heparin based on 
uronic acid content. 
Mast cell granules were isolated from 90 to 95% purified rat mast cells.  The mast cells were 
suspended to a  concentration of 4  ×  10  e cells per ml in 0.0075 M Tris, pH 7.4, containing 0.01 M 
NaC1,  8  x  10 -4 M  magnesium chloride and 10 pg/ml deoxyribonuclease.  The cells were frozen 
and thawed six times, and the debris was sedimented at 400 g  for 10 rain at room temperature. 
The supernate containing granules was decanted and sedimented at 3,000 g  for 20 rain at 4°C 
(12).  The resulting granule pellet was stored at -70°C until it was resusponded in 0.0075 M Tris, 
pH 7.4, assayed for uronic acid content and used for c~)mplement studies. 
Complement Components and Assays.  Half-isotonic Veronal-buffered saline, pH 7.5, contain- 
ing  0.1%  gelatin  and  2.5%  dextrose  (DGVB),  DGVB  with  0.5  mM  magnesium  and  0.15  mM 
calcium  (DGVB++),  DGVB  containing  0.01  M  ethylenediamine  tetraacetate  (EDTA)  (EDTA- 
DGVB), and isotonic Veronal-buffered saline containing 0.1% gelatin and 0.04 M EDTA (0.04 M 
EDTA-GVB) were used as diluents in hemolytic assays. JOHN  M.  WEILER  ET  AL.  411 
C3  (18-20),  B  (21),  D  (22),  properdin  (P)  (23),  ~IH  (24),  CoVF  (25),  and  C3b  inactivator 
(C3bINA) (26) were purified to homogeneity and quantitated as described. C3b was generated by 
incubating purified C3 with CoVF-dependent C3 convertase  (CoVFBb) bound to Sepharose 4B 
(27); the C3b thus generated was devoid of hemolytic C3,  B,  and  D  activities.  Guinea pig C1, 
guinea  pig  C2  (28),  and  C3  nephritic  factor  (C3NeF)  (29)  were  functionally  purified  and 
quantitated  as  described.  Rat  serum  was obtained from  Microbiological Associates,  Bethesda, 
Md. 
EAC4b,3b cellular intermediates (30) were prepared at a ratio of 100/~g C3 per 10  ~ EAC1,4b,2a 
cells unless otherwise noted.  B  hemolytic activity in reaction mixtures of purified proteins (26) 
was assayed as described (31). 
Results 
Inhibition  of Formation  of Amplification  Pathway  Convertases.  Dose-re- 
sponse  effects of both  commercial  and  RPMC  heparin  on  the  formation of 
C3b,Bb,  stabilized  by  P  or  C3NeF  or  unstabilized,  and  on  the  convertase 
formed without 13  so as to contain uncleared B  were studied.  1 ml reaction 
mixtures yielding approximately one convertase site per cell consisted of: 0.45 
ng  B,  0.10  /xg  13,  and  0.65  gg  P  per  l0  s  EAC4b,3b  for  formation  of 
EAC4b,3b,Bb,P; 1.2 ng B, 0.10 ttg ]3, and 0.079 U C3NeF per l0  s EAC4b,3b for 
EAC4b,3b,Bb,NeF; 4.5 ng B and 0.10/xg b  per l0  s EAC4b,3b for EAC4b,3b,Bb; 
and  224  ng  B  per  l0  s  EAC4b,3b  for EAC4b,3b,B.  A  0.1-ml  portion  of each 
mixture  was  added  to  0.1  ml  DGVB  ÷+  alone  or  containing  commercial  or 
RPMC heparin and incubated 30 rain at 30°C with shaking. Three-tenths ml of 
a 1:20 dilution of rat serum in 0.04 M EDTA-GVB (C-EDTA) was added to each 
reaction  mixture,  and  incubation  was  continued for  60  min  at  37°C. After 
addition of 1.5 ml saline, percent lysis was measured and the average number 
of hemolytic sites per cell  (Z)  were calculated (Fig.  1).  Formation of all four 
types of convertase sites was inhibited by heparin in a  dose-related manner, 
with the  EAC4b,3b,B  being the least sensitive. The commercial and  RPMC 
heparin  had  similar  activities  on  a  weight  basis.  Dialysis  of  commercial 
heparin against cation-containing (DGVB ++) or noncation-containing (DGVB) 
buffer overnight at 4°C did not diminish its inhibitory action, indicating that 
chelation of cations was not the mechanism of its inhibitory effect. 
It  was  necessary  to  introduce  heparin  with  the  C-EDTA  to  exclude  a 
significant inhibitory  effect  of heparin  upon  the  developing  reagent.  1  ml 
DGVB  ÷+ containing 1  ×  l0  s EAC4b,3b,  1.87 ng B,  0.10  gg 13,  and 0.65  /xg P 
was incubated with shaking for 30  min at 30°C to form EAC4b,3b,Bb,P.  One 
tenth-ml  portions  were  then  added  to  0.1  ml  0.04  M  EDTA-GVB  alone  or 
containing varying amounts of commercial heparin, followed immediately by 
addition of 0.3 ml C-EDTA. Incubation was continued for 60 min at 37°C, and 
percent lysis was determined. A 0.1 ml portion of the starting mixture was also 
incubated with 8.66  ttg commercial heparin during convertase formation and 
developed with 0.1  ml 0.04  M  EDTA-GVB  and 0.3  ml C-EDTA.  Commercial 
heparin, 86.6/xg per 107 cells, inhibited hemolysis by C-EDTA of the erythro- 
cytes bearing the preformed convertase by only 8%, whereas 1/10 this concentra- 
tion per 107 cells gave 99% inhibition of convertase formation. 
To analyze further the site of heparin action on convertase formation, the 
quantity of cell-bound C3b was varied and the amount of B  input adjusted to 
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FXG.  1.  Dose-response  effects  of native (A) and commercial (B) heparin on the formation 
of EAC4b,3b,Bb,P (0  O), EAC4b,3b,Bb,NeF (&  A), EAC4b,3b,Bb (I  -'), and 
EAC4b,3b,B (O  O). 
a  ratio  of 1  /~g  C3  (low),  10  ~g  C3  (medium),  or  100  ~g C3  (high)  per  109 
EAC1,4b,2a (30). Low, medium, and high EAC4b,3b, 2 ×  108, were mixed with 
0.2 ftg ]3,  1.3/~g P, and 90, 9 and 0.75 ng B, respectively, in 2 ml DGVB  +÷. One 
tenth-ml portions  of each  mixture were  added to  0.1  ml  DGVB  ÷÷  alone,  to 
DGVB  ÷+  containing RPMC  heparin,  and to  DGVB  ÷÷ containing commercial 
heparin and incubated for 30  rain at 30°C. C-EDTA was then added, and the 
convertase sites were developed. The cells prepared with the least amount of 
C3 and requiring the highest amount of B to be lysed were profoundly inhibited 
by both RPMC and commercial heparin, while cells prepared with the highest 
amount of C3 and requiring the least amount of B to be lysed were relatively 
resistant to inhibition by heparin (Fig. 2). 
The kinetics of inhibition by heparin of formation of unstabilized convertase 
were  then  examined.  Two-tenths  ~g  of B  alone,  with  7.8  ~g  commercial 
heparin,  and with 3.9  /~g commercial heparin  were pre-incubated in  1.8  ml 
DGVB  ++ for 10 min at 30°C. Three portions containing 1.8  ×  108 EAC4b,3b and 
0.18  ~g ]3  in  1.8  ml  DGVB  ++  were also preincubated.  These reactants were 
then  brought to  37°C and  mixed  together at  time zero.  At  timed  intervals 
thereafter,  0.2-ml  samples  were  removed and  added to  C-EDTA  to  develop 
convertase sites. The Tma  x was 5 rain and the Zmax was 0.84 in buffer (Fig. 3). 
The Tma  x was not appreciably changed by the two concentrations of commercial 
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FIG. 2.  Dose-response effects of native (A) and commercial (B) heparin on the formation 
of EAC4b,3b,Bb,P using EAC4b,3b prepared with low (0  O), medium (.  I), and 
high (A  A) C3 inputs.  The number of hemolytic sites per cell were 1.4, 1.7, and 1.6, 
respectively. 
The  fluid  phase  interaction  of C3b  and  B  was  examined  to  determine  if 
heparin  inhibition  was  due  to  impaired  B  utilization.  Reaction  mixtures 
containing 0.5 ~g C3b and 20 ng D  alone and with incremental concentrations 
of commercial or RPMC  heparin in  150  ~1  DGVB ++ were prewarmed at 30°C, 
and at time zero 1.1 ftg B in 50/~1 DGVB ++ at 30°C was introduced. Incubation 
was  continued at  30°C,  and  at timed intervals  10  /~l was  removed from each 
reaction mixture, added to 0.5 ml ice cold DGVB ++, and assayed for residual B 
(Fig.  4).  RPMC heparin at 4  pg per reaction mixture and commercial heparin 
at 0.9 ~g and 4.3 ~g per reaction mixture inhibited fluid phase consumption of 
B, thereby indicating that heparin decreased convertase formation by decreas- 
ing B  utilization. 
The effect of a  single high dose of commercial heparin on the decay rates of 
unstabilized  and  P  or  C3NeF-stabilized  convertase  was  examined.  Reaction 
mixtures containing 1.2  x  108 EAC4b,3b cells, 0.67 ng B, 0.12 pg I) and 0.77 ftg 
P  to form EAC4b,3b,Bb,P;  1.2  x  10  s EAC4b,3b cells, 1.68 ng B, 0.12/zg I), and 
0.095 U  C3NeF to form EAC4b,3b,Bb,NeF;  and 1.2  x  108 EAC4b,3b cells,  6.72 
ng  B  and  0.12  /~g  ])  to  form  EAC4b,3b,Bb,  each  in  1.2  ml  DGVB ++,  were 
prepared in duplicate and incubated for 30 rain at 30°C. The cellular intermedi- 
ates  were  washed  twice  in  EDTA-DGVB,  resuspended  in  1.2  ml  of EDTA- 
DGVB alone or in EDTA-DGVB containing 43.3/~g commercial heparin per 10  ~ 414  MODULATION  OF  FORMATION  OF  C3b,Bb  BY  HEPARIN 
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FIG.  4.  Kinetics of B consumption by fluid phase C3b and I:) alone (O  O) and in the 
presence  of  increasing  concentrations  of  RPMC  (A)  or  commercial  (B)  heparin.  The 
amounts of RPMC  heparin were 4  ~g (A  A) and 0.8  ~g (D  El) and of commercial 
heparin  were  4.3  ~ag  (A  A),  0.9  ~g  (D  El),  and  0.2  ~g  (O  O)  in  the  0.2  ml 
reaction mixtures. Z expresses the residual fluid phase concentration of B in terms of the 
capacity to form hemolytic sites per cell. 
cells,  and  decayed at  30°C. Two-tenths-ml  portions  were  removed at  timed 
intervals  and  added to  0.3  ml  C-EDTA to  develop residual convertase sites 
(Fig.  5).  The half-lives of 5-1/2 min and 40 min of the unstabilized convertase 
and the C3NeF-stabilized  convertase, respectively, were not changed by the 
presence  of heparin.  In  contrast,  the  half-life of 48  min  of the  P-stabilized 
convertase decreased to  26  rain  in  the  presence of 43.3  ~tg heparin  per  107 1.0 
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FIG. 5.  Decay of  hemolytic  sites  on EAC4b,3b,Bb (I  I), EAC4b,3b,Bb,P ($  0) 
and  EAC4b,3b,Bb,NeF (&  b)  in  buffer  alone  and  in  the  presence  of  43.3  ~g  commercial 
heparin  per  107  cells,  respectively  (~  O, ©  ©, ~  A). 
cellular  intermediates, suggesting that this  high dose of  heparin had no direct 
effect  on the convertase but rather had an effect  on P. 
Effect of Heparin on the Regulatory Proteins, ~IH, and C3blNA.  The 
effect  of  heparin on ~IH and C3bINA was also determined to assess further the 
capacity Of  heparin to modulate convertase expression. 2 x 10  s  EAC4b,3b, 1.5 
ng B; 0.20  ~g ]3, and 1.3/~g P in 2 ml DGVB  ++, or 2 x 10  s  EAC4b,3b, 56 ng B, 
and 0.20 /~g ]3 in 2 ml DGVB  ++ were incubated for 30 rain at 30°C to form 
EAC4b,3b,Bb,P and EAC4b,3b,Bb, respectively.  One-tenth-ml portions of  each 
intermediate were added  to  0.2  ml EDTA-DGVB  alone  or  EDTA-DGVB  contain- 
ing 16 ng ~IH,  or varying dilutions of commercial  heparin,  or both. The 
reaction mixtures were incubated for  an additional 15 rain  at 30°C, and residual 
convertase sites  were developed.  ~IH alone inhibited 58% of  the P-stabilized 
sites  and 56% of  the unstabilized sites  (Fig.  6). Increasing amounts of  heparin 
inhibited the ~IH effect  on the unstabilized convertase, with 8.7 fig/107  cells 
fully inhibiting ~IH acceleration of decay. With the P-stabilized convertase, 
low concentrations of  heparin inhibited flirt-dependent decay, whereas higher 
amounts of heparin were directly  inhibitory,  presumably through removal of 
P-stabilization. 
Seven-tenths  ~g  C3bINA,  0.7  ~g C3bINA  and  incremental  amounts  of 
commercial heparin, and incremental amounts of  commercial heparin alone,  in 
0.2 ml DGVB  ++, and the buffer alone were incubated for 15 rain  at 30°C. One- 
tenth ml DGVB  ++ containing 1 ×  10  ~ EAC4b,3b was added to each mixture, 
and incubation was continued for 30 rain  at 37°C. 3 ml ice cold DGVB  ++ was 
then added to each mixture, and the cells  were washed twice in the same 
buffer. The cells  were resuspended in 0.2 ml DGVB  ++ containing 0.056 ng B, 416  MODULATION  OF  FORMATION  OF  C3b,Bb  BY  HEPARIN 
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FIG.  6.  Dose-response  effects of commercial heparin  on inhibition of EAC4b,3b,Bb,P 
(O  O) and EAC4b,3b,Bb (m  m) and on inhibition of these intermediates in the 
presence of a  constant amount of ~IH  (O  O and  []  •,  respectively). Percent 
inhibition refers to residual sites per cell (Z) as compared  to decay in buffer alone. 
0.01  ~g I3 and 0.065/~g P and incubated for 30 min more at 30°C. C-EDTA was 
then added to develop the convertase sites. C3bINA inactivated 35% of the C3b 
sites on the cellular intermediate; and the presence of 5.4,  10.8,  21.7, and 43.3 
pg commercial heparin did not alter this result.  When the EAC4b,3b interme- 
diate was incubated with heparin alone and then washed, its ability to be lysed 
was not affected. 
Inhibition  of Formation  of Amplification  Pathway Convertase  by Isolated 
RPMC Granules.  RPMC granules were suspended in 0.0075  M "Iris at pH 7.4 
and studied for their effect on the formation of the P-stabilized amplification 
convertase, C3b,Bb,P. 1 ml DGVB  ++ containing 0.56 ng B, 0.10/~g ]:), 0.65 ~g  P 
and 1 x  10  s EAC4b,3b was added in 0.1-ml portions to 0.1 ml DGVB  ++ alone or 
to  DGVB  ++  containing  incremental  amounts  of RPMC  heparin  or  RPMC 
granules.  The  reaction  mixtures  were  incubated  for  30  min  at  30°C.  The 
cellular intermediates were then washed three times with 3 ml DGVB  ++ and 
resuspended in 0.2  ml DGVB  ++,  and  C-EDTA was added to develop residual 
hemolytic  sites.  The  RPMC  granule  heparin,  quantitated  by  uronic  acid 
content,  inhibited  the  formation  of the  amplification  pathway  convertase, 
C3b,Bb,P, in a manner comparable to solubilized, isolated RPMC heparin (Fig. 
7). 
Discussion 
Native  macromolecular rat  mast  cell and  commercial hog heparin  inhibit 
generation of the amplification convertase C3b,Bb, thus modulating a  critical 
step in the complement sequence. The inhibitory action of heparin was not due 
to chelation of magnesium,  since equilibration of heparin  with  calcium and 
magnesium-containing  buffer did  not  diminish  its  inhibitory  activity.  Both 
native  and  commercial heparin  inhibit  generation of the  I:)-independent C3 JOHN  M.  WEILER  ET  AL.  417 
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FIG.  7.  Dose-response effects of RPMC heparin (©  O) and RPMC granules (0 
on the formation of EAC4b,3b,Bb,P. 
e) 
convertase, C3b,B, as well as the ]3-dependent convertase, C3b,Bb, even in the 
presence  of P  and  C3NeF-stabilization,  thereby  suggesting  an  effect on  the 
interaction of C3b and B rather than on ]3 or on the stabilizing principles (Fig. 
1).  Heparin  was  most  active  in  impairing  convertase  formation  on  cellular 
intermediates formed with the lowest C3 input and developed with the highest 
B  concentration,  thereby suggesting  an  inhibitory  action on the  C3b binding 
site for B that is essential for convertase formation (Fig. 2). Heparin treatment 
of the EAC4b,3b intermediate followed by washing did not reduce site formation 
with B  and  ]3, thereby suggesting  a  reversible inhibitory  action on C3b.  The 
kinetics of unstabilized convertase (C3b,Bb) formation (Fig. 3) were not appre- 
ciably altered  when heparin  suppressed the  total  number  of sites generated, 
and  heparin  did not accelerate  decay of the  unstabilized  convertase  (Fig.  5). 
Taken together, these studies indicate that native and commercial heparin,  in 
a  concentration of less than  1 pg per 107 cellular intermediates,  act to prevent 
effective interaction of C3b and B, most likely by reversible action on C3b. This 
interpretation  is  strengthened  by the  demonstration  that  heparin  does  not 
inactivate B and, indeed, prevents B utilization in a  fluid phase interaction of 
C3b, B, and ]3 (Fig. 4). 
The concentration  of native or commercial heparin  which inhibited  C3b,Bb 
formation by about 50% on a  cellular intermediate  limited to about 1 site per 
cell  was  0.3  to  0.6  ~g/10  ~ cells  (Fig.  1).  A  concentration  of 4.5  to  20  ~g/ml 
inhibited the fluid phase utilization of B by C3b in the presence of 13 by about 
50%  (Fig.  4).  A  much higher  concentration  of commercial  heparin  had  previ- 
ously been observed to inhibit the electrophoretic conversion of B by ]3 in the 
presence of C3b  (32).  These  concentrations  of 1-10  pg/ml  are  comparable  to 
those in which the  anti-coagulant  and  anti-thrombin  HI cofactor activities of 
native and commercial heparin are expressed (11). This concentration range is 
the same as that in which commercial heparin has been reported to inhibit the 
reactive  lysis  phenomenon  (9)  and  the  binding  of hemolytic  C1  (4),  and  to 
augment the action of the C1 esterase inhibitor  (8). A concentration of heparin 
50-fold  greater  than  that  required  to  inhibit  formation  of unstabilized  and 418  MODULATION  OF  FORMATION  OF  C3b,Bb  BY  HEPARIN 
stabilized  convertases did not alter the decay rate of unstabilized or C3NeF- 
stabilized  convertase (Fig. 5) but did accelerate the decay of the P-stabilized 
convertase, thereby implying a direct  effect  on P at this  high dose. 
Heparin in a concentration range of  0.54-8.66 ~g per 10  z  cells  inhibited the 
capacity of  ~IH to accelerate  the decay of  the unstabilized convertase (Fig.  6). 
This finding serves to distinguish further the action of heparin from that of 
/31H. Heparin  interference with the ~IH  effect was  also observed in the 
presence of the P-stabilized  convertase, but interpretation of the result  was 
more complex because of the capacity of heparin itself  to accelerate decay of 
this form of stabilized  convertase. Heparin had no effect  on the inactivating 
action of C3bINA on cell-bound C3b. The finding that heparin could prevent 
convertase formation on one hand and theoretically  increase convertase forma- 
tion  through supression of  ~IH regulatory action on the other may account for 
some of the apparently paradoxical effects  of heparin seen in some patients 
with paroxysmal nocturnal hemoglobinuria (33). 
Native rat mast cell  heparin proteoglycan was as active  on a weight basis  in 
inhibiting convertase  formation  as commercial  heparin,  which  represents 
glycosaminoglycan  side chains cleaved from the original hog proteoglycan. 
Heparin in the mast cell  granule is bound in large part to a highly cationic 
chymotrypsin-like protease, whose proteolytic  activity  is appreciably masked 
until the granule is solubilized (34)  in high salt.  In contrast, the mast cell 
granule did express anticomplementary activity  on convertase formation (Fig. 
7). A  regulatory action of the mast cell  via its granules on the alternative 
complement pathway could be relevant to the role  of  these two effector  systems 
in  helminthic infections.  Helminths not  only  stimulate  a marked IgE-dependent 
hypersensitivity  response but are  themselves direct  activators  of  the alternative 
complement pathway  (35,  36).  Activation of the tissue mast cells would alter 
local vascular permeability to bring both plasma proteins as well as inflamma- 
tory cells to that  site.  Human  skin  contains  between 5,000  and  10,000  mast 
cells per mm  3 (37) and there is at least 0.1 pg heparin per 10,000 rat mast cells 
(11,  34).  Thus,  if  the  human  mast  cell  contains  heparin  in  any  amount 
comparable  to  that  of the  rat,  the  concentrations  available  in  some  tissues 
would  appear  to  be  sufficient  to  modulate  the  amplification  phase  of the 
alternative pathway. 
Summary 
Native rat mast cell  macromolecular heparin proteoglycan and commercial 
hog heparin glycosaminoglycan chains inhibit  generation of  the amplification 
convertase, C3b,Bb. The inhibitory action of  heparin is not due to chelation of 
magnesium.  Heparin  is most active in inhibiting convertase  formation on 
cellular intermediates formed with the lowest C3b input and developed with 
the highest B concentration, thereby suggesting the receptor site  for B on C3b 
as the point of heparin action. This interpretation is consistent with the 
demonstration  that heparin prevents B  utilization  during the fluid phase 
interaction  of  C3b, B, and D. 
Inhibition is observed also  when C3b,Bb generation takes place on cellular 
intermediates in the presence of P or C3NeF, which yield  stabilized  forms of JOHN  M.  WEILER  ET  AL.  419 
the convertase.  50 times  the  concentration  of heparin  required  to inhibit 
convertase generation does not accelerate the decay of the unstabilized or the 
C3NeF-stabilized convertases and has only a modest effect  on the P-stabilized 
convertase. An additional effect  of heparin is to impair ~lH-mediated  decay- 
dissociation of C3b,Bb.  The  concentration  of native or commercial  heparin 
which prevents convertase formation is in the same range as that required for 
the demonstration of  its  anti-coagulant and anti-thrombin HI cofactor  activities. 
The additional finding that this  inhibitory action of  heparin can be expressed 
by the isolated mast cell  granule suggests that native heparin may contribute 
to the modulation of the amplification pathway of  complement. 
Received for publication 25 August 1977. 
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